Background/aims: Emerging evidence showed the long noncoding RNA X-inactive specific transcript (lncRNA XIST) may play a crucial role in various cancers. However, its prognostic value in cancer patients remains controversial. Therefore, we performed an indepth meta-analysis to investigate the potential clinical value of lncRNA XIST as a prognostic marker for cancer patients.
Introduction
Long noncoding RNA (lncRNA) is a kind of RNA without protein-coding function, which is identified more than 200 nucleotides in length. [1] Accumulating evidence have been showed lncRNA participated in a variety of biological and pathological processes and involved in a variety of human diseases, such as autoimmune disease, degenerative disease and cancer, etc. [2] [3] [4] Dysregulation of lncRNA in cancer may affect specific microRNAs or downstream genes expression, thus plays vital role in cancer initiation and progression. [5] To date, there are several lncRNAs have been identified as prognostic biomarkers in various cancers. [6] [7] [8] [9] [10] The lncRNA X-inactive specific transcript (XIST) is derived from XIST gene, recently have been found differentially expressed in multiple cancers and influenced several aggressive phenotypes in tumor cells, such as non-small cell lung carcinoma (NSCLC), [11] gastric carcinoma, [12] nasopharyngeal carcinoma, [13] etc. And certain retrospective clinical studies investigated its expression in patient tumor samples, indicating that lncXIST may correlate with clinicopathological parameters and predict survival outcomes in cancer patients. [14, 15] Nevertheless, discrepancies existed among different cancer types and patient number was limited. For instance, most of the studies revealed elevated expression of lncXIST promoted cancer progression and was associated with poor prognosis. [11] [12] [13] [14] However, the study conducted by Du et al showed it may function as a tumor suppressor in prostate cancer. [16] Therefore, a comprehensive systematic review and metaanalysis was performed based on eligible retrospective studies, aiming to precisely investigate the potential prognostic value of lncXIST for cancer patients.
Materials and methods

Literature search strategy
We performed literature search using PubMed (ncbi.nlm.nih.gov/ pubmed), Embase (embase.com) and the Cochrane Library (cochranelibrary.com) up to January 2018. Search terms used as follows: ("X inactive-specific transcript" OR "XIST" OR "long noncoding RNA XIST" OR "lncRNA XIST") AND ("cancer" OR "carcinoma" OR "tumor" OR "neoplasm"). Review articles and references of original studies were also searched by hand to find potential articles. This study protocol was conducted according to the PRISMA statement and approved by the institutional review board at Xiangya Hospital of Central South University.
Inclusion and exclusion criteria
Eligible studies should meet the following selection criteria. Inclusion criteria:
1. studies evaluated the association between lncRNA XIST and cancer patient samples; 2. prognosis outcomes or clinicopathologic features were reported; 3. sufficient information to estimate hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (95% CI); 4. studies published in English.
Exclusion criteria:
1. article types including case report, review, conference abstract, editorial and letter, etc; 2. studies with insufficient data to estimate HR or OR with related 95% CI; 3. publications without clinical data.
Data extraction and quality assessment
Eligible articles were reviewed by 2 reviewers independently according to the above inclusion and exclusion criteria (Chen J and Yang X). Disagreement was resolved during a consensus with a third reviewer (Zu X). The following information was extracted: author name, publication year, country or region, patient number, study type, tumor type, gender, age, tumor size, clinical TMN stage, follow-up time, therapies, detecting methods for lncXIST, cut-off value, lymph node metastasis, distant metastasis, survival outcomes, such as overall survival (OS), and disease free survival (DFS). The HRs were obtained directly or indirectly from included articles according to the study of Tierney et al. [17] The Newcastle-Ottawa Scale (NOS) was used to assess the quality of studies.
Statistical analysis
The meta-analysis was performed using STATA 12.0 version software (Stata Corporation, College Station, TX). The pooled HRs with 95% CI were evaluated for OS, DFS. And pooled ORs with 95% CI were evaluated for gender, age, tumor size, tumor clinical stage, lymph node metastasis, and distant metastasis status. Subgroup analysis and sensitivity test were also performed. Statistical heterogeneity among studies was checked using a Chi-square-based Q test and I-squared value. A fixedeffects model was used if P value for the heterogeneity test was greater than .05; Otherwise, the random-effects model was used. Publication bias was evaluated by Egger and Begg test. [18, 19] P < .05 was considered statistically significant.
Results
Study selection and characteristics
A total of 227 records were retrieved through databases and other sources. According to the inclusion and exclusion criteria, our present meta-analysis finally included 18 eligible retrospective studies with 1351 cancer patients (Fig. 1) . Specifically, for prognostic evaluation, data was obtained from 12 studies on lncXIST expression and cancer patient OS and 3 studies on DFS. For clinicopathological parameters correlation, there were 12 studies on gender, 15 studies on age, 14 studies on tumor size, 13 studies on clinical stage, 9 studies on lymph node metastasis, and 5 studies on distant metastasis. The main characteristics of the eligible studies were summarized in Table 1 . For the quality assessment, the NewcastleOttawa Scale (NOS) score of individual cohort studies was ranged from 6 to 8 (Table 1) . [11] [12] [13] [14] [15] [16] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 
LncRNA XIST expression and cancer patients OS and DFS
There are 12 studies reported the association between lncRNA XIST expression and OS of 1011 cancer patients. There was a statistical heterogeneity between trials (I-squared = 67%; P < .001), so a random effects model was used in the analysis. Overall, high expression of lncRNA XIST was associated with poor OS (HR = 2.14, 95% CI = 1.26-3.64; P = .005). The subgroup analysis based on the cancer type revealed its expression correlated with OS in digestive system cancer (HR = 2.93, 95% CI = 1.91-4.49; P < .001) ( Fig. 2A ). And subgroup analysis based on the cut-off value of lncRNA XIST showed its expression associated with OS in median cut-off group (HR = 2.27, 95% CI = 1.17-4.40; P = .015) (Fig. 2B ). Three studies reported the association between lncRNA XIST expression and DFS of 265 cancer patients. There was a statistical heterogeneity between trials (I-squared = 72.5%; P = .026), so a random effects model was used in the analysis. Overall, high expression of lncRNA XIST was associated with poor DFS (HR = 4.52, 95% CI = 1.42-14.37; P = .011) (Fig. 2C ).
3.3. LncRNA XIST expression and cancer patients clinicopathologic features 3.3.1. Gender. There are 12 studies reported the association between lncRNA XIST expression and gender of 904 cancer patients. There was no statistical heterogeneity between trials (I-squared = 0%; P = .494), so a fixed effects model was used in the analysis. Overall, no significant association was observed between expression of lncRNA XIST and gender difference (OR = 1.02, 95% CI = 0.77-1.34; P = .907).
Age.
Fifteen studies reported the association between lncRNA XIST expression and age of 926 cancer patients. There was no statistical heterogeneity between trials (I-squared = 0%; P = .751), so a fixed effects model was used in the analysis. Overall, no significant association was observed between expression of lncRNA XIST and age (OR = 0.80, 95% CI = 0.62-1.02; P = .074). Since different cut-off values of age were described, we subsequently conducted subgroup analysis. Results showed lncRNA XIST expression was not associated with patient age in ≥ 60 y vs < 60 y group (OR = 0.74, 95% CI = 0.54-1.02; P = .065), ≥ 45 y vs < 45 y group (OR = 1.14, 95% CI = 0.69-1.88; P = .613) and other group (OR = 0.60, 95% CI = 0.31-1.15; P = .121), respectively.
3.3.3. Tumor size. There were 14 studies reported lncRNA XIST expression and tumor size with 1020 cancer patients. There was no statistical heterogeneity between trials (I-squared = 0%; P = .668), so a fixed effects model was used in the analysis. Overall, higher expression of lncRNA XIST was linked to larger tumor size (OR = 2.93, 95% CI = 2.24-3.84; P < .001). Since different cut-off values of tumor size were described, we subsequently conducted subgroup analysis. Results showed lncRNA XIST expression was associated with tumor size in ≥ 5 cm vs < 5 cm group (OR = 2.92, 95% CI = 2.07-4.13; P < .001) and ≥ 3 cm vs < 3 cm group (OR = 2.95, 95% CI = 1.91-4.55; P < .001), respectively (Fig. 3). 3.3.4. Clinical TMN stage. There were 13 studies reported lncRNA XIST expression and clinical TMN stage with 962 cancer patients. There was a statistical heterogeneity between trials (I-squared = 69.2%; P < .001), so a random effects model was used in the analysis. Overall, expression of lncRNA XIST [31] DFS = Disease-free survival, NA = Not applicable, NOS = Newcastle-Ottawa Scale, NSCLC = non-small cell lung cancer, OS = overall survival, qRT-PCR = quantitative real-time reverse transcription polymerase chain reaction, XIST = X inactive-specific transcript.
Chen et al. Medicine (2019) 98:3 www.md-journal.com was associated with tumor clinical stage (OR = 2.73, 95% CI = 1.62-4.58; P < .001). Since different stage cut-off values were described, we subsequently conducted subgroup analysis. Results showed lncRNA XIST expression was associated with TMN stage in III-IV vs. I-II group (OR = 3.09, 95% CI = 2.06-4.62; P < .001). While, this association was not observed in the other group (OR = 1.65, 95% CI = 0.16-17.12; P = .065) (Fig. 4) .
3.3.5. Lymph node metastasis. There were 9 studies reported lncRNA XIST expression and lymph node metastasis status with 619 cancer patients. There was no statistical heterogeneity between trials (I-squared = 0%; P = .447), so a fixed effects model was used in the analysis. Overall, expression of lncRNA XIST was associated with lymph node metastasis (OR = 2.44, 95% CI = 1.74-3.42; P < .001). Also, we conducted subgroup analysis based on cancer type. Results showed lncRNA XIST expression was associated with lymph node metastasis in digestive system group (OR = 2.62, 95% CI = 1.71-4.02; P < .001) and genitourinary system group (OR = 2.44, 95% CI = 1.74-3.42; P = .004), respectively. While, this association was not observed in the respiratory system group (OR = 1.50, 95% CI = 0.74-3.03; P = .264) (Fig. 5 ).
3.3.6. Distant metastasis. There were 5 studies reported lncRNA XIST expression and distant metastasis status with 397 cancer patients. There was a statistical heterogeneity between trials (I-squared = 82.7%; P < .001), so a random effects model was used in the analysis. Overall, expression of lncRNA XIST was not associated with distant metastasis (OR = 1.59, 95% CI = 0.55-4.63; P = .393). Subgroup analysis based on cancer type revealed that lncRNA XIST expression was associated with distant metastasis in digestive system group (OR = 2.90, 95% CI = 1.80-4.68; P < .001).
The detailed meta-analysis and subgroup analysis results for lncRNA XIST expression and cancer patient clinicopathological parameters are listed in Table 2 .
Sensitivity analysis and publication bias
Sensitivity analysis was performed by exclusion of each single study to assess the stability of present pooled results. After removing those documents that led to heterogeneity, the overall HR or OR did not change significantly, so the current metaanalysis results were relatively stable (Fig. 6) . Furthermore, Begg funnel plot and Egger regression test were performed to evaluate the publication bias. No evidence of publication bias was identified using Begg funnel plots (Fig. 7) , which was further validated by Egger regression test (P > .05). 
Discussion
Recent studies have provided novel insights into the functions and potential mechanisms of IncRNA XIST in cancer development. Yao et al found lncRNA XIST expression was up-regulated in glioblastoma cancer stem cells, knocking down this lncRNA exerted tumor-suppressive functions by upregulating miR-152. [32] Several studies uncovered it may also influence the epithelial-mesenchymal transition (EMT) process in multiple cancers. Chen et al demonstrated it expedited metastasis by competing with miR-200b-3p to modulate the ZEB1 expression and boost EMT in colorectal cancer. [22] Zhuang et al revealed the lncXIST/miR-92b/Smad7 signaling axis promoted hepatocellular carcinoma (HCC) progression. [33] Zhang et al found lncXIST could promote gastric cancer (GC) progression through TGF-b1 via targeting miR-185. [34] Despite the ceRNA mechanisms, some studies dissected it may directly regulate protein expression or function. Fang et al showed lncXIST may act as an oncogene in non-small cell lung cancer (NSCLC) by epigenetically repressing KLF2 expression. [20] McHugh et al demonstrated it could silence transcription by directly interacting with SHARP, recruiting SMRT, activating HDAC3, and deacetylating histones to exclude Pol II across the X chromosome. [35] Tumor cell invasion and drug chemoresistance are 2 crucial problems for cancer therapeutics. In Du et al's study, they verified LnXIST could interact with miR-29c through DNA mismatch repair pathway to modulate the chemoresistance of glioma cell to temozolomide, which is one of the most commonly used drug in glioma chemotherapy. [24] Results from Sun et al showed Knocking down lncRNA XIST enhanced the chemosensitivity of NSCLC cells via suppression of autophagy. They provided preclinical evidence that the lncXIST/miR-17/autophagy pathway may be a promising target for patients with chemoresistant NSCLC. [25] The in vitro and in vivo experiments demonstrated lncXIST may affect tumor progression in multiple potential pathways. In addition, several clinical sample surveys also confirmed these findings. Compared with para-carcinoma tissues, lncXIST aberrant expressed in tumor tissues, and its increased level was associated with shorter survival and poorer prognosis. [12] [13] [14] [15] [21] [22] [23] [24] [26] [27] [28] 30, 31] Further, overexpression of lncRNA XIST in tumor tissues associated with clinicopathological features in cancer patients. [11, 12, [20] [21] [22] [23] However, this correlation seems Chen et al. Medicine (2019) 98:3 www.md-journal.com reversed in prostate cancer. Investigation from Du et al revealed lncXIST was down-regulated in prostate cancer specimens and low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients. [16] In this meta-analysis, we pooled data from a total of 18 retrospective eligible studies with 1351 cancer patients. Results revealed that high lncRNA XIST expression was an unfavorable prognostic factor in multiple cancer patients. For the survival analysis, high expression of lncRNA XIST was associated with poor OS (HR = 2.14, 95% CI = 1.26-3.64; P = .005). The subgroup analysis showed its expression correlated with OS in digestive system cancer (HR = 2.93, 95% CI = 1.91-4.49; P < .001) and median cut-off group (HR = 2.27, 95% CI = 1.17-4.40; P = .015). Also, high expression of lncRNA XIST was associated with poor DFS (HR = 4.52, 95% CI = 1.42-14.37; P = .011). The clinicopathological parameters analysis demonstrated that increased XIST expression was significantly associated with larger tumor size (OR = 2.93, 95% CI = 2.24-3.84; P < .001), higher clinical stage (OR = 2.73, 95% CI = 1.62-4.58; P < .001) and easier lymph node metastasis (OR = 2.44, 95% CI = 1.74-3.42; P < .001). In addition, subgroup analysis revealed that lncRNA XIST expression correlated with distant metastasis in digestive cancer (OR = 2.90, 95% CI = 1.80-4.68; P < .001). However, no significant association was observed between expression of lncRNA XIST and gender difference (OR = 1.02, 95% CI = 0.77-1.34; P = .907) as well as age (OR = 0.80, 95% CI = 0.62-1.02; P = .074).
Nevertheless, a comprehensive and in-depth meta-analysis was performed, there are several limitations should be considered. Firstly, several HRs were calculated based on data extracted from the survival curve, which may not be very accurate. Secondly, heterogeneity was observed in some analysis including OS, DFS, TMN stage and distant metastasis. Accordingly, subgroup analysis was performed to find potential associations. Thirdly, all included studies are retrospective and most of the studies are from China, some geographical factors may vary across different populations.
Conclusion
Our meta-analysis results revealed lncRNA XIST level served as a prognostic indicator in multiple cancers. Higher expression could predict cancer patient poor OS and DFS. Also, its expression correlated with tumor size, TMN stage and lymph node metastasis in multiple cancers as well as distant metastasis in digestive system cancer. Further clinical studies are still required and more mechanism researches are needed to explore the precise role of lncXIST in cancer. Table 2 Meta-analysis of the association between lncRNA XIST expression and clinicopathological parameters in cancer patients.
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